abstract |
The present invention relates to the use of LRIG2 for the treatment or diagnosis of cancer. In particular, the present invention relates to a pharmaceutical composition for preventing or treating endometrial cancer, which comprises an LRIG2 (leucine-rich repeats and immunoglobulin-like domains 2) gene or a protein encoded by the gene as an active ingredient, A biomarker, a composition for diagnosing endometrial cancer, a kit for diagnosing endometrial cancer, and a method for screening a therapeutic agent for endometrial cancer. |